Golden Helix Receives NIH-SBIR Phase 2 Grant 2R44 GM128485-02

Golden Helix, Inc. has announced themselves as the recipient of an NIH SBIR Grant 2R44GM128485-02 entitled “Automated and Guided Workflows for Clinical Testing Using NGS Assays.”

“With the help of this grant, we will take the clinical automation of NGS data to the next level, focusing on germline diseases and cancer diagnostics,” states Andreas Scherer, Ph.D., President, and CEO of Golden Helix, Inc. “We are eternally grateful for the NIH’s incredible support. The first results of the work based on this grant will be presented at AMP Global 2019 in Hong Kong this May.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.